Mogelijk gemaakt door 
Translate
Translate
November 24, 2025
Announcement no. 28
Managers’ transactions
In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 27, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated |
| ||
a) Name | Jens Due Olsen | ||
2 Reason for the notification |
| ||
a) Position/status | Chair of the Board of Directors of BioPorto A/S | ||
b) Initial notification/Amendment | Initial notification | ||
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||
a) Name | BioPorto A/S | ||
b) LEI | 5299004SWFL5JAN4W830 | ||
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| ||
a) Description of the financial instrument, type of instrument | Shares | ||
b) Nature of the transaction | Subscription of new shares in connection with private placement | ||
c) Price(s) and volume(s) | Price: DKK 1.072, Volume: 2,798,507 | ||
d) Aggregated information | Average price per share: DKK 1.072 | ||
e) Date of the transaction | 2025-11-24, at 7:13 a.m. UTC (8:13 a.m. CET) | ||
f) Place of the transaction | Outside a trading venue | ||
1 Details of the person discharging managerial responsibilities/person closely associated |
| |
a) Name | Henrik Juuel | |
2 Reason for the notification |
| |
a) Position/status | Vice Chair of the Board of Directors of BioPorto A/S | |
b) Initial notification/Amendment | Initial notification | |
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| |
a) Name | BioPorto A/S | |
b) LEI | 5299004SWFL5JAN4W830 | |
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| |
a) Description of the financial instrument, type of instrument | Shares | |
b) Nature of the transaction | Subscription of new shares in connection with private placement | |
c) Price(s) and volume(s) | Price: DKK 1.072, Volume: 93,283 | |
d) Aggregated information | Average price per share: DKK 1.072 | |
e) Date of the transaction | 2025-11-24, at 7:13 a.m. UTC (8:13 a.m. CET) | |
f) Place of the transaction | Outside a trading venue | |
1 Details of the person discharging managerial responsibilities/person closely associated |
| |
a) Name | Mats Thorén | |
2 Reason for the notification |
| |
a) Position/status | Member of the Board of Directors of BioPorto A/S | |
b) Initial notification/Amendment | Initial notification | |
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| |
a) Name | BioPorto A/S | |
b) LEI | 5299004SWFL5JAN4W830 | |
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| |
a) Description of the financial instrument, type of instrument | Shares | |
b) Nature of the transaction | Subscription of new shares in connection with private placement | |
c) Price(s) and volume(s) | Price: DKK 1.072, Volume: 233,208 | |
d) Aggregated information | Average price per share: DKK 1.072 | |
e) Date of the transaction | 2025-11-24, at 7:13 a.m. UTC (8:13 a.m. CET) | |
f) Place of the transaction | Outside a trading venue | |
1 Details of the person discharging managerial responsibilities/person closely associated |
| |
a) Name | Carsten Buhl | |
2 Reason for the notification |
| |
a) Position/status | Chief Executive Officer of BioPorto A/S | |
b) Initial notification/Amendment | Initial notification | |
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| |
a) Name | BioPorto A/S | |
b) LEI | 5299004SWFL5JAN4W830 | |
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| |
a) Description of the financial instrument, type of instrument | Shares | |
b) Nature of the transaction | Subscription of new shares in connection with private placement | |
c) Price(s) and volume(s) | Price: DKK 1.072, Volume: 1,399,253 | |
d) Aggregated information | Average price per share: DKK 1.072 | |
e) Date of the transaction | 2025-11-24, at 7:13 a.m. UTC (8:13 a.m. CET) | |
f) Place of the transaction | Outside a trading venue | |
1 Details of the person discharging managerial responsibilities/person closely associated |
| |
a) Name | Niels Høy Nielsen | |
2 Reason for the notification |
| |
a) Position/status | Chief Financial Officer of BioPorto A/S | |
b) Initial notification/Amendment | Initial notification | |
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| |
a) Name | BioPorto A/S | |
b) LEI | 5299004SWFL5JAN4W830 | |
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| |
a) Description of the financial instrument, type of instrument | Shares | |
b) Nature of the transaction | Subscription of new shares in connection with private placement | |
c) Price(s) and volume(s) | Price: DKK 1.072, Volume: 233,208 | |
d) Aggregated information | Average price per share: DKK 1.072 | |
e) Date of the transaction | 2025-11-24, at 7:13 a.m. UTC (8:13 a.m. CET) | |
f) Place of the transaction | Outside a trading venue | |
1 Details of the person discharging managerial responsibilities/person closely associated |
| |
a) Name | Gry Husby Larsen | |
2 Reason for the notification |
| |
a) Position/status | Chief Legal Officer of BioPorto A/S | |
b) Initial notification/Amendment | Initial notification | |
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| |
a) Name | BioPorto A/S | |
b) LEI | 5299004SWFL5JAN4W830 | |
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| |
a) Description of the financial instrument, type of instrument | Shares | |
b) Nature of the transaction | Subscription of new shares in connection with private placement | |
c) Price(s) and volume(s) | Price: DKK 1.072, Volume: 233,208 | |
d) Aggregated information | Average price per share: DKK 1.072 | |
e) Date of the transaction | 2025-11-24, at 7:13 a.m. UTC (8:13 a.m. CET) | |
f) Place of the transaction | Outside a trading venue | |
To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/.
Investor Relations contacts
Niels Høy Nielsen, BioPorto A/S, investor@bioporto.com, C: +45 45290000
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.
Attachment
